B2M encodes a critical component of the major histocompatibility complex class I molecule, which is required for the presentation of tumor antigens to CD8+ T cells, and alterations in B2M have been associated with decreased B2M expression and acquired resistance to ICIs51. Here, CD8A is linked to neoplasm.